Valuation: Valneva SE

Market Cap 465M 519M 428M 388M 725M 49.32B 738M 5.1B 2.05B 25.94B 1.95B 1.91B 81.82B P/E 2026 *
-5.63x
P/E 2027 * 8.88x
Enterprise Value 599M 669M 551M 500M 934M 63.54B 951M 6.57B 2.64B 33.43B 2.51B 2.46B 105B EV / Sales 2026 *
3.97x
EV / Sales 2027 * 1.86x
Free-Float
89.58%
Yield 2026 *
-
Yield 2027 * -
1 day-4.55%
1 week+3.61%
Current month-11.88%
1 month-11.88%
3 months+7.15%
6 months+1.30%
Current year-38.21%
1 week 5.32
Extreme 5.32
5.77
1 month 5.25
Extreme 5.25
6.04
Current year 4.75
Extreme 4.75
12.18
1 year 4.75
Extreme 4.75
12.18
3 years 3.62
Extreme 3.62
14.49
5 years 3.62
Extreme 3.62
67.84
10 years 3.62
Extreme 3.62
67.84
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 28/07/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 19/12/2023
Director/Board Member 75 06/03/2013
Chairman 65 19/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%+3.61% - - 519M
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.15%+7.54%+47.86%+206.32% 43.82B
Weighted average by Cap. +0.17%+5.44%+48.50%+186.13%

Financials

2026 *2027 *
Net sales 151M 168M 139M 126M 235M 15.99B 239M 1.65B 664M 8.41B 632M 619M 26.53B 283M 316M 261M 236M 441M 30.04B 450M 3.11B 1.25B 15.8B 1.19B 1.16B 49.83B
Net income -81.35M -90.84M -74.83M -67.8M -127M -8.62B -129M -892M -358M -4.54B -341M -334M -14.31B 53.02M 59.2M 48.77M 44.19M 82.61M 5.62B 84.15M 582M 233M 2.96B 222M 217M 9.33B
Net Debt 134M 150M 123M 112M 209M 14.22B 213M 1.47B 591M 7.48B 562M 550M 23.6B 62.86M 70.19M 57.82M 52.39M 97.93M 6.66B 99.76M 690M 277M 3.51B 263M 258M 11.06B
Projected Income Statement - Annual - Valneva SE
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change Volume
30/10/26 US$5.450 -4.55% 7,929
29/10/26 US$5.710 -0.52% 11,516
28/10/26 US$5.740 +3.05% 3,854
27/10/26 US$5.570 +2.96% 16,134
26/10/26 US$5.410 +2.85% 21,301
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Valneva SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.453EUR
Average target price
6.200EUR
Spread / Average Target
+152.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Valneva SE